Jim Cramer says investors are too focused on AI stocks. Here’s where he says to look instead

Jim Cramer urged investors to reduce concentration in volatile AI data-center stocks through November's midterm elections and diversify into overlooked sectors. He highlighted GE Aerospace's nearly $12 billion acquisition of Consolidated Precision Products, fintech names Robinhood and Affirm, healthcare companies Hinge Health and Medtronic, and energy-infrastructure dividend payers Enbridge and Enterprise Products Partners, both yielding more than 5%. Cramer also argued Amgen's 10% sympathy-driven selloff following Novartis's failed late-stage cholesterol-drug trial may have already priced in much of the risk.

Analysis

The actionable implication is not a broad rotation out of AI, but a selective reduction in crowded beta where earnings revisions are already carrying elevated expectations. Media-driven calls for diversification are not themselves catalysts; however, a two-month period of elevated political and rate uncertainty could favor businesses with idiosyncratic earnings drivers and lower multiple sensitivity. HOOD and AFRM are poor substitutes for AI concentration: both remain levered to retail-risk appetite, crypto activity, consumer credit performance and potential regulatory scrutiny, making their apparent diversification benefit limited in a risk-off tape.

GE's vertical integration can improve engine delivery reliability and protect aftermarket economics, but the more important second-order effect is that independent aerospace casting capacity becomes scarcer for rival engine and airframe supply chains. BA benefits only if production bottlenecks are genuinely component-led; certification, quality-control and supplier-wide labor constraints remain more material risks, so the stock should not be treated as a clean read-through. The key diligence item is acquisition financing and implied return on invested capital: a large premium or material leverage increase would turn a supply-chain positive into a GE multiple-compression risk over the next 1-3 months.

MDT offers a cleaner defensive re-rating setup if organic growth and margin progression persist through the next earnings cycle; its muted reaction suggests expectations remain below a sustainable improvement path. EPD is the preferable energy-infrastructure exposure because export-volume and fractionation economics can capture changing trade flows, whereas ENB's regulated/contracted model is more exposed to rates and CAD/USD than to near-term commodity dislocation. AMGN's selloff should not be assumed to be fully discounted: a competitor's clinical failure may be target-validation risk rather than a transferable valuation opportunity, and no long is warranted before mechanistic differentiation and trial endpoints are verified.

Key Decisions for Investors

• Initiate a 3-6 month long MDT / short XLV pair, sized market-neutral. Thesis is company-specific earnings and margin revision rather than a healthcare beta call; target 8-12% relative upside. Exit if the next report shows organic growth deceleration or guidance fails to support further operating-margin expansion.
• Place GE on a post-deal diligence watch rather than chase immediately: enter only if financing preserves investment-grade balance-sheet flexibility and management quantifies production/aftermarket synergies. A 6-12 month long GE versus short BA can express supply-chain de-risking, but invalidate if BA delivery recovery outpaces GE engine shipments or deal leverage materially exceeds expectations.
• Accumulate EPD on weakness for a 6-18 month income-and-volume thesis; use ENB only as a lower-beta alternative, not as a direct geopolitical-flow trade. Risk/reward is impaired if US export volumes weaken, NGL spreads compress, or energy-flow disruption normalizes; a break in these operating indicators should trigger a reassessment.
• Avoid adding directional HOOD or AFRM exposure solely as an AI-diversification trade over the next 1-3 months. Revisit HOOD after evidence that non-crypto revenue retains momentum through lower retail activity, and AFRM only after delinquency, funding-cost and merchant-subsidy data confirm that growth is converting to durable contribution-margin expansion.
• Do not bottom-fish AMGN ahead of additional clinical differentiation data. A long becomes investable only if its candidate's endpoint design or mechanism demonstrably avoids the read-through from the failed comparator; otherwise, further target-class de-risking can pressure the multiple despite a seemingly inexpensive entry point.